Photo by kaziminmizan from unsplash
R enal transplantation usually requires the administra-tion of lifelong immunosuppressive therapy to mini-mize rejection. 1 However, while these immunosuppressants are vital to graft protection, they increase the risk of infection… Click to show full abstract
R enal transplantation usually requires the administra-tion of lifelong immunosuppressive therapy to mini-mize rejection. 1 However, while these immunosuppressants are vital to graft protection, they increase the risk of infection and malignancy. Posttransplant lymphoproliferative disorder (PTLD), a troublesome combination of both, covers a wide range of lymphomas, most commonly B-cell type and has been described in pediatric and adult patients. 2 Risk factors for PTLD include Epstein-Barr virus (EBV) infection and immunosuppression and the prevalence of adult kidney transplant PTLD is estimated to be 0.5% to 4%, with the highest incidences occurring within the first year of transplant. 2-5 Although most cases are associated with EBV, EBV-negative PTLD has been described in the literature and is associated with worse outcomes. 4 sepsis-like
Journal Title: Transplantation Direct
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!